Status:
COMPLETED
Studies of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine
Lead Sponsor:
Tulane University Health Sciences Center
Collaborating Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Malaria
Eligibility:
All Genders
21-45 years
Phase:
PHASE1
Brief Summary
The purpose of this protocol is to perform Phase 1 (safety/toxicity and pharmacokinetic) Studies of an investigational aminoquinoline antimalarial (AQ-13) in human subjects. The compound to be studied...
Detailed Description
Study Population: Healthy young men and women 21-45 years of age who are taking no chronic medications with the exception of birth control pills will be invited to participate in this Phase 1 Study a...
Eligibility Criteria
Inclusion
- Healthy adult volunteers from 21 to 45 years of age
Exclusion
- Chronic medications with the exception of oral contraceptives Pregnancy Breast-feeding
Key Trial Info
Start Date :
August 1 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2005
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT00323375
Start Date
August 1 1999
End Date
August 31 2005
Last Update
December 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tulane-LSU-Charity Hospital General Clinical Research Center
New Orleans, Louisiana, United States, 70112